New hope for hepatitis c: triple therapy shows promise in untreated patients
NCT ID NCT00780416
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new drug called MP-424 (Telaprevir) added to the standard two-drug therapy for hepatitis C. It involved 189 adults with genotype 1 hepatitis C who had never been treated before. The goal was to see if the triple combination could clear the virus from the blood for at least 24 weeks after treatment ended.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Telaprevir (MP-424) combined with peginterferon alfa-2b and ribavirin
- What this could lead to
- If successful, this could lead to a more effective treatment for hepatitis C, helping more patients clear the virus.
- What could go wrong
- This is a completed Phase 3 trial, but results may not apply to all patients, and side effects from the drug combination can be significant.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATITIS C are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Toranomon Hospital
Kawasaki, Takatsu-ku, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A Finger-Prick could change the fight against hepatitis c
- A simple finger prick could transform hepatitis c care
- Can coaching clinics curb HIV? a new strategy puts it to the test
- Can hepatitis c be cured in just 4 weeks? a new trial puts it to the test
- Can a simple roadside test catch liver disease before it turns deadly?
- Pharmacy-Based hepatitis c testing could cure more people on opioid therapy